The LANDMARK trial: early outcomes of a randomised non-inferiority trial comparing TAVI devices

In this video, Christopher Cook interviews Patrick Serruys about the late-breaking clinical trial data from the LANDMARK RCT. Patrick Serruys begins by explaining the LANDMARK trial, which compares TAVI devices, and emphasizes the complexity of applying VARC-3 criteria. He highlights that the 30-day outcomes confirm the non-inferiority of the new THV compared to two widely used contemporary THVs, before noting that the 10-year results will be crucial to assess long-term durability and outcomes. He also discusses how this new valve addresses the issue of intermediate sizing, preventing oversizing or undersizing, and its potential impact on the fitting region and pacemaker usage.

This interview was filmed at EuroPCR 2024: see more videos here.